Clinical Spectrum, Treatments and Outcomes of VEXAS Syndrome: A Multicenter Belgian Cohort
This retrospective study of a multicenter Belgian cohort of 21 male patients characterizes VEXAS syndrome as a clinically heterogeneous late-onset autoinflammatory disease with frequent hematologic and systemic manifestations, substantial infectious morbidity and mortality, and variable responses to second-line targeted therapies like anti-IL-6 agents and JAK inhibitors.